CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
No Interventiongenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03804021
NCT03804021N/ACompleted
CompareCT.gov

Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency

Adverum Biotechnologies, Inc.·observational·Posted Jan 15, 2019·Updated Sep 20, 2024

In Brief

An observational study evaluating No Intervention for Alpha-1 Antitrypsin Deficiency. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treatment of Alpha-1 Antitrypsin (A1AT) deficiency.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlpha-1 Antitrypsin Deficiency
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 15, 2019
Enrollment StartDec 27, 2018
Primary CompletionDec 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.5 years ago

Interventions

No Interventiongenetic

Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)